Furthermore, in patients with high-risk HER2-negative early breast cancer (neoadjuvant setting, I-SPY2 trial), combining ganetespib (150 mg/m2 every 3 weeks) with paclitaxel (weekly for 12 weeks) improved pathological complete response (pCR) rates to 26–38% compared to 22% in the control group; however, it did not meet the criteria for progression to phase III clinical trials, and it remains uncertain whether this combination substantially improves outcomes compared to standard adjuvant therapy [69]. Here, ERBB2 is linked to breast carcinoma.